• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant mFOLFIRINOX for resectable pancreatic cancer: increasing evidence, ongoing challenges.

作者信息

Neilson Taylor, Cloyd Jordan M

机构信息

Department of Surgery, Ohio State University, Columbus, OH, USA.

Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

出版信息

Transl Gastroenterol Hepatol. 2025 Mar 24;10:22. doi: 10.21037/tgh-24-135. eCollection 2025.

DOI:10.21037/tgh-24-135
PMID:40337772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056118/
Abstract
摘要

相似文献

1
Neoadjuvant mFOLFIRINOX for resectable pancreatic cancer: increasing evidence, ongoing challenges.新辅助mFOLFIRINOX方案用于可切除胰腺癌：证据不断增加，挑战仍在持续。
Transl Gastroenterol Hepatol. 2025 Mar 24;10:22. doi: 10.21037/tgh-24-135. eCollection 2025.
2
Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.可切除和交界可切除胰腺导管腺癌的新辅助和辅助治疗：日本胰腺导管腺癌治疗的现状。
Gut Liver. 2023 Sep 15;17(5):698-710. doi: 10.5009/gnl220311. Epub 2023 Feb 27.
3
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.可切除胰腺癌的围手术期或辅助 mFOLFIRINOX 治疗（PREOPANC-3）：一项多中心随机对照试验的研究方案。
BMC Cancer. 2023 Aug 7;23(1):728. doi: 10.1186/s12885-023-11141-5.
4
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效：A021501 期随机临床试验。
JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.
5
Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.手术和围手术期治疗在可切除的胰腺导管腺癌老年患者中的作用。
Oncologist. 2020 Nov;25(11):e1681-e1690. doi: 10.1634/theoncologist.2020-0086. Epub 2020 Aug 4.
6
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.使用mFOLFIRINOX方案对可切除胰腺导管腺癌进行的一线全身治疗：一项试点研究。
J Surg Oncol. 2018 Mar;117(3):354-362. doi: 10.1002/jso.24872. Epub 2017 Oct 16.
7
Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).胰腺癌的治疗——可切除胰腺癌（胰腺导管腺癌）的新辅助治疗
Transl Gastroenterol Hepatol. 2019 Mar 27;4:21. doi: 10.21037/tgh.2019.03.05. eCollection 2019.
8
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.高分辨率胰腺 CT 评估胰腺导管腺癌可切除性：一项多中心前瞻性研究。
Eur Radiol. 2023 Sep;33(9):5965-5975. doi: 10.1007/s00330-023-09584-2. Epub 2023 Mar 29.
9
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.术前使用 mFOLFIRINOX 或吉西他滨/ Nab-紫杉醇 +/- 等毒量立体定向体部放射治疗（iHD-SBRT）治疗边界可切除胰腺腺癌（STEREOPAC 试验）：一项随机比较多中心 II 期试验的研究方案。
BMC Cancer. 2023 Sep 21;23(1):891. doi: 10.1186/s12885-023-11327-x.
10
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.可切除胰腺癌的系统化疗临床试验：综述。
JAMA Surg. 2021 Jul 1;156(7):663-672. doi: 10.1001/jamasurg.2021.0149.

本文引用的文献

1
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌新辅助治疗的最佳实践
JAMA Surg. 2025 Feb 1;160(2):172-180. doi: 10.1001/jamasurg.2024.5191.
2
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.可切除胰腺癌的围手术期改良 FOLFIRINOX：一项非随机对照试验。
JAMA Oncol. 2024 Aug 1;10(8):1027-1035. doi: 10.1001/jamaoncol.2024.1575.
3
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.
新辅助治疗后未能行切除术治疗可切除胰腺癌：SWOG S1505 的二次分析。
J Natl Compr Canc Netw. 2024 Apr 29;22(4):e237099. doi: 10.6004/jnccn.2023.7099.
4
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较（NORPACT-1）：一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.
5
Surgical management of pancreatic ductal adenocarcinoma: a narrative review.胰腺导管腺癌的外科治疗：一篇叙述性综述
Transl Gastroenterol Hepatol. 2023 Sep 7;8:39. doi: 10.21037/tgh-23-27. eCollection 2023.
6
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.在 PDAC 患者接受新辅助化疗后，持久细胞表型导致预后不良。
Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7.
7
Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.在两项随机试验中，基线血清碳水化合物抗原 19-9 水平对可切除和交界可切除胰腺癌患者新辅助放化疗治疗效果的预测价值。
Br J Surg. 2023 Sep 6;110(10):1374-1380. doi: 10.1093/bjs/znad210.
8
Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.局部胰腺癌新辅助治疗后的手术切除率：荟萃分析
Br J Surg. 2022 Dec 13;110(1):34-42. doi: 10.1093/bjs/znac354.
9
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌新辅助治疗的患者偏好
Pancreas. 2022 Jul 1;51(6):657-662. doi: 10.1097/MPA.0000000000002083. Epub 2022 Sep 13.
10
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.可切除和交界可切除胰腺癌的新辅助治疗或 upfront 手术：随机对照试验的荟萃分析。
Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.